Favorable Response to Pemetrexed as a Salvage Agent for Patients with Advanced Lung Cancer Who Have Failed Conventional Platinum-Based Chemotherapy and EGFR Tyrosine Kinase Inhibitors

Research output: Contribution to journalArticle

Abstract

Background: For locally advanced or metastatic non-squamous non-small cell lung cancer
(NSCLC), pemetrexed is currently recommended as first-line treatment in combination with
platinum agents or second-line chemotherapy after the disease has become refractory to platinum-based
doublet regimens, but few reports have addressed its role as salvage chemotherapy
after failure of multiple therapies and the relationship between response rate and EGFR and
K-ras mutations.
Methods: We retrospectively evaluated the efficacy of pemetrexed in 11 patients with advanced
NSCLC, who had failed at least platinum-based doublet combinations and erlotinib or gefitinib.
The gender, performance status, number of cycles given, EGFR and K-ras mutation status, best
response, adverse reactions, time to progression (TTP) and overall survival (OS) were used to
assess the effects.
Results: A median of 6.17 cycles of infusion was given. Six out of 11 patients experienced partial
response, three stable disease and two disease progression. The TTP and OS of salvage pemetrexed
therapy were 108 and 346 days, respectively. The EGFR mutation status did not affect
its efficacy. It was well-tolerated and required no dose modification.
Conclusions: Pemetrexed is a good option for patients with good performance status who have
failed platinum- and taxane-containing regimens and EGFR tyrosine kinase inhibitors.
Original languageEnglish
Pages (from-to)281-286
Number of pages6
Journal中華民國癌症醫學會雜誌
Volume25
Issue number4
Publication statusPublished - Aug 2009

Fingerprint

Pemetrexed
Proxy
Platinum
Protein-Tyrosine Kinases
Lung Neoplasms
Drug Therapy
Mutation
Survival
Non-Small Cell Lung Carcinoma
Disease Progression
Therapeutics

Keywords

  • 非小細胞型肺癌
  • EGFR 酪氨酸激酶抑制劑
  • pemetrexed
  • Non-small cell lung cancer
  • EGFR tyrosine kinase inhibitors

Cite this

@article{05cd9b9d75f64b6fb7a7b8299d055f41,
title = "Favorable Response to Pemetrexed as a Salvage Agent for Patients with Advanced Lung Cancer Who Have Failed Conventional Platinum-Based Chemotherapy and EGFR Tyrosine Kinase Inhibitors",
abstract = "Background: For locally advanced or metastatic non-squamous non-small cell lung cancer(NSCLC), pemetrexed is currently recommended as first-line treatment in combination withplatinum agents or second-line chemotherapy after the disease has become refractory to platinum-baseddoublet regimens, but few reports have addressed its role as salvage chemotherapyafter failure of multiple therapies and the relationship between response rate and EGFR andK-ras mutations.Methods: We retrospectively evaluated the efficacy of pemetrexed in 11 patients with advancedNSCLC, who had failed at least platinum-based doublet combinations and erlotinib or gefitinib.The gender, performance status, number of cycles given, EGFR and K-ras mutation status, bestresponse, adverse reactions, time to progression (TTP) and overall survival (OS) were used toassess the effects.Results: A median of 6.17 cycles of infusion was given. Six out of 11 patients experienced partialresponse, three stable disease and two disease progression. The TTP and OS of salvage pemetrexedtherapy were 108 and 346 days, respectively. The EGFR mutation status did not affectits efficacy. It was well-tolerated and required no dose modification.Conclusions: Pemetrexed is a good option for patients with good performance status who havefailed platinum- and taxane-containing regimens and EGFR tyrosine kinase inhibitors.",
keywords = "非小細胞型肺癌, EGFR 酪氨酸激酶抑制劑, pemetrexed, Non-small cell lung cancer, EGFR tyrosine kinase inhibitors, 非小細胞型肺癌, EGFR 酪氨酸激酶抑制劑, pemetrexed, Non-small cell lung cancer, EGFR tyrosine kinase inhibitors",
author = "Hung, {Wen Yueh} and Chun-Nin Lee and Kuan-Jen Bai and Ming-Chih Yu and Chang, {Jer Hwa} and Hsu, {Han Lin} and Hsingjin-Eugene Liu",
year = "2009",
month = "8",
language = "English",
volume = "25",
pages = "281--286",
journal = "中華民國癌症醫學會雜誌",
issn = "1015-6267",
publisher = "中華民國癌症醫學會",
number = "4",

}

TY - JOUR

T1 - Favorable Response to Pemetrexed as a Salvage Agent for Patients with Advanced Lung Cancer Who Have Failed Conventional Platinum-Based Chemotherapy and EGFR Tyrosine Kinase Inhibitors

AU - Hung, Wen Yueh

AU - Lee, Chun-Nin

AU - Bai, Kuan-Jen

AU - Yu, Ming-Chih

AU - Chang, Jer Hwa

AU - Hsu, Han Lin

AU - Liu, Hsingjin-Eugene

PY - 2009/8

Y1 - 2009/8

N2 - Background: For locally advanced or metastatic non-squamous non-small cell lung cancer(NSCLC), pemetrexed is currently recommended as first-line treatment in combination withplatinum agents or second-line chemotherapy after the disease has become refractory to platinum-baseddoublet regimens, but few reports have addressed its role as salvage chemotherapyafter failure of multiple therapies and the relationship between response rate and EGFR andK-ras mutations.Methods: We retrospectively evaluated the efficacy of pemetrexed in 11 patients with advancedNSCLC, who had failed at least platinum-based doublet combinations and erlotinib or gefitinib.The gender, performance status, number of cycles given, EGFR and K-ras mutation status, bestresponse, adverse reactions, time to progression (TTP) and overall survival (OS) were used toassess the effects.Results: A median of 6.17 cycles of infusion was given. Six out of 11 patients experienced partialresponse, three stable disease and two disease progression. The TTP and OS of salvage pemetrexedtherapy were 108 and 346 days, respectively. The EGFR mutation status did not affectits efficacy. It was well-tolerated and required no dose modification.Conclusions: Pemetrexed is a good option for patients with good performance status who havefailed platinum- and taxane-containing regimens and EGFR tyrosine kinase inhibitors.

AB - Background: For locally advanced or metastatic non-squamous non-small cell lung cancer(NSCLC), pemetrexed is currently recommended as first-line treatment in combination withplatinum agents or second-line chemotherapy after the disease has become refractory to platinum-baseddoublet regimens, but few reports have addressed its role as salvage chemotherapyafter failure of multiple therapies and the relationship between response rate and EGFR andK-ras mutations.Methods: We retrospectively evaluated the efficacy of pemetrexed in 11 patients with advancedNSCLC, who had failed at least platinum-based doublet combinations and erlotinib or gefitinib.The gender, performance status, number of cycles given, EGFR and K-ras mutation status, bestresponse, adverse reactions, time to progression (TTP) and overall survival (OS) were used toassess the effects.Results: A median of 6.17 cycles of infusion was given. Six out of 11 patients experienced partialresponse, three stable disease and two disease progression. The TTP and OS of salvage pemetrexedtherapy were 108 and 346 days, respectively. The EGFR mutation status did not affectits efficacy. It was well-tolerated and required no dose modification.Conclusions: Pemetrexed is a good option for patients with good performance status who havefailed platinum- and taxane-containing regimens and EGFR tyrosine kinase inhibitors.

KW - 非小細胞型肺癌

KW - EGFR 酪氨酸激酶抑制劑

KW - pemetrexed

KW - Non-small cell lung cancer

KW - EGFR tyrosine kinase inhibitors

KW - 非小細胞型肺癌

KW - EGFR 酪氨酸激酶抑制劑

KW - pemetrexed

KW - Non-small cell lung cancer

KW - EGFR tyrosine kinase inhibitors

UR - http://www.cos.org.tw/Jour/Letter.asp?sub=2&Continue=Y

M3 - Article

VL - 25

SP - 281

EP - 286

JO - 中華民國癌症醫學會雜誌

JF - 中華民國癌症醫學會雜誌

SN - 1015-6267

IS - 4

ER -